From the 1Department of Obstetrics, Gynecology and Reproductive Sciences and Magee-Womens Research Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania; 2Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania; 3Department of Obstetrics and Gynecology, Oregon Health and Science University, Portland, Oregon; 4Department of Obstetrics and Gynecology, Northwestern University, Chicago, Illinois; and 5Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, California.
See related article on 895.
* For members of the MAST Study Trial Group, see the Appendix.
Supported by an anonymous foundation.
Presented in part as an oral abstract at the 2006 Annual Meeting of the Association of Reproductive Health Professionals and Society of Family Planning, LaJolla, California, September 7–9, 2006.
Corresponding author: Mitchell D. Creinin, MD, University of Pittsburgh School of Medicine, Department of Obstetrics, Gynecology and Reproductive Sciences, Magee-Womens Hospital, 300 Halket Street, Pittsburgh, PA 15213-3180; e-mail: [email protected].
Financial Disclosure: Dr. Creinin receives compensation from Danco Laboratories, LLC, the distributor of mifepristone in the United States, for providing third-party telephone consults to clinicians who call for expert advice on mifepristone.